SymBiosis Capital Management

SymBiosis Capital Management is a venture capital firm dedicated to advancing biotherapeutics innovations for serious and life-threatening diseases. The firm invests in groundbreaking medicines across various disease areas, financing stages, and geographies, with a particular emphasis on programs in or about to enter human trials. SymBiosis currently manages a portfolio of more than 30 investments and has significant, long-term capital commitments to fund future investments.

Founded in 2021 and headquartered in Bentonville, Arkansas, SymBiosis is led by Managing Partner Chidozie Ugwumba, who brings extensive experience in partnering with companies developing innovative medicines. The firm's investment strategy is to support private companies with promising biotherapeutic programs, aiming to address unmet medical needs and improve patient outcomes.

SymBiosis Capital Management's approach combines deep industry expertise with a commitment to advancing medical breakthroughs. By focusing on early-stage investments in the biotherapeutics sector, the firm seeks to drive the development of transformative therapies that can make a significant impact on global health.